Erisyon is transforming the field of proteomics with the world’s first single molecule protein sequencer. With unprecedented sensitivity and scalability for proteomics, Erisyon enables new applications across the Life Sciences
Erisyon has emerged from the University of Texas at Austin to commercialize the world’s first single molecule protein sequencer. Inheriting work developed over the course of the past decade at UT’s Center for Systems and Synthetic Biology, Erisyon was founded by a group of technologists and entrepreneurs with the ambition to usher in new discoveries that make the world healthier, safer, and more abundant.
Company Details
- Employees
- 16
- Founded
- -
- Address
- 360 Nueces St, Austin,texas,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- erisyon.com
- Keywords
- single molecule protein sequencing, diagnostics, oncology, plant sciences, drug development, industrial biology.
- HQ
- Austin, Texas
Erisyon Questions
Erisyon's website is erisyon.com
Erisyon's LinkedIn profile is https://www.linkedin.com/company/erisyon
Erisyon has
16 employees.
View email and phone details for 16
employees at Erisyon.
Erisyon's industry is
Biotechnology Research
Erisyon's top competitors are
Quantum-Si,
Qana Therapeutics,
Everlume Bio,
Genopore,
Nautilus Biotechnology,
Portal Biotech,
Revi Life Sciences,
Encodia,
Glyphic Biotechnologies,
Superbrewed Food Inc..
Erisyon's categories are Biotechnology Research
Erisyon's founding year is 2018
